Background:Ziltivekimab, a novel human IgG1, k antibody directed against IL-6 ligand, may improve inflammation and hyporesponsiveness to erythropoiesis-stimulating agents ESAs in patients receiving maintenance hemodialysis HD, according to new study findings.